%0 Journal Article
%T Benefit of tamoxifen in estrogen receptor positive DCIS of the breast
%A Fausto, Petrelli
%A Barni, Sandro
%J Gland Surgery
%D 2012
%B 2012
%9 
%! Benefit of tamoxifen in estrogen receptor positive DCIS of the breast
%K 
%X Allred and colleagues recently published, in Journal of Clinical Oncology, a retrospective analysis which illustrates the benefits of tamoxifen (TAM) in ductal carcinoma in situ (DCIS) according to the estrogen receptor (ER) status (1). The analysis included 41% of the original sample of the NSABP24 trial (2). TAM reduced the hazard of relapse by 50% at 10 years of follow-up among 76% patients resulting ER+ in this trial. No benefit was observed in ER-patients with DCIS. The strength of this analysis was the centralisation of receptor analysis, in the majority of cases, according to standard immunohistochemical analysis.
%U https://gs.amegroups.org/article/view/600
%V 1
%N 1
%P 3-4
%@ 2227-8575